LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
106.07
+0.33 (+0.31%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close105.74
Open105.72
Bid0.00 x 800
Ask0.00 x 1800
Day's Range104.22 - 106.11
52 Week Range73.69 - 107.84
Volume3,761,998
Avg. Volume3,536,853
Market Cap105.805B
Beta0.48
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.25 (2.13%)
Ex-Dividend Date2018-08-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Animal health firm Elanco surges 41 percent on debut
    Reuters14 hours ago

    Animal health firm Elanco surges 41 percent on debut

    The company raised $1.51 billion from the offering, which it expects to largely pass on to Eli Lilly and Co (LLY.N). The U.S. drugmaker is expected to own about 82.3 percent of Elanco after the IPO, which was announced in July following a nine-month review of Lilly's businesses which include diabetes and lung cancer drugs.

  • MarketWatch16 hours ago

    Elanco Animal Health stock soars more than 35% in trading debut

    Elanco Animal Health Inc. shares soared more than 35% Thursday in their trading debut, after the company priced the stock above its price range. Elanco, a spinoff from Eli Lilly & Co. , issued 62.9 million shares at $24 each, compared with a price range of $20 to $23, to raise $1.51 billion. Goldman Sachs. J.P. Morgan and Morgan Stanley were book-running managers on the deal. Shares are trading on the New York Stock Exchange under the ticker "ELAN."

  • Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
    Zacks17 hours ago

    Eli Lilly Prices Animal Health Unit IPO at $24 Per Share

    Lilly (LLY) prices Elanco IPO at $24 per share which is above the expected range of $20-$23 per share.

  • Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
    Market Realist18 hours ago

    Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates

    GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

  • Elanco’s $1.7 billion IPO looks too pricey, and here’s why
    MarketWatch19 hours ago

    Elanco’s $1.7 billion IPO looks too pricey, and here’s why

    Elanco Animal Health, the premier animal-health company being spun out of Eli Lilly (LLY) , is expected to begin trading on Thursday. Elanco enters the public market with significant revenue ($2.9 billion in 2017) but falling after-tax profit (NOPAT), and negative GAAP net income. As with any health-care firm, the valuation is based less on current profitability and more on the strength of its product/vaccine portfolio (and their patents) and its success in researching and developing (or acquiring) new animal-health products.

  • Reutersyesterday

    Lilly's Elanco animal health unit's IPO priced at $24/share

    The initial public offering of Eli Lilly Co's animal health unit, Elanco, was priced above the expected range at $24 per share on Wednesday, giving the company a market capitalization of $8.55 billion. Elanco raised $1.51 billion from the IPO of 62.9 million shares. Lilly, which sold only a minority stake in the IPO, announced the separation of the unit in July following a nine-month review.

  • MarketWatchyesterday

    Elanco Animal Health prices IPO above expected range

    Elanco Animal Health Inc. priced shares for its initial public offering above the estimated range late Wednesday. The animal drug company, which is being spun off from Eli Lilly & Co. , priced shares at $24 a piece. Earlier in the month, Elanco had estimated shares in the $20 to $23 range. Under current pricing, Elanco hopes to raise up to $1.74 billion on an offering of 62.9 million shares with an added 9.4 million to underwriters to cover over-allotments. Following the IPO, Lilly expects to keep an 82.3% stake in Elanco, or 80.2% if over-allotment shares are sold. Goldman Sachs. J.P. Morgan and Morgan Stanley are acting as book-running managers. Shares are scheduled to begin trading under the ticker "ELAN" on the New York Stock Exchange on Thursday.

  • Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO
    Bloomberg2 days ago

    Lilly's Elanco Rises After $1.5 Billion Animal-Health IPO

    The Eli Lilly & Co.-owned animal medicine maker rose to $32.11 from its $24 offering price at 11:40 a.m. Thursday in New York trading, giving it a market value of $11.7 billion. Elanco priced 62.9 million shares on Wednesday, after marketing them at $20 to $23 each. Elanco already operates fairly independently from its soon-to-be former parent, which will help it move quickly once it’s on its own, according to Chief Executive Officer Jeff Simmons.

  • J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
    Zacks2 days ago

    J&J Files NDA for Erdafitinib in Urothelial Cancer Indication

    Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking approval of pan-FGFR inhibitor, erdafitinib, for the treatment of metastatic urothelial cancer, a type of bladder cancer.

  • Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff
    Zacks2 days ago

    Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

    Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist2 days ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
    Zacks3 days ago

    Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

    Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

  • Exploring Pharmaceutical Stocks’ Revenue Growth Rates
    Market Realist3 days ago

    Exploring Pharmaceutical Stocks’ Revenue Growth Rates

    In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • A Look at the Dividends Paid by Pharma Stocks in 2018
    Market Realist3 days ago

    A Look at the Dividends Paid by Pharma Stocks in 2018

    In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
    Zacks3 days ago

    Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV

    Glaxo (GSK) submits a regulatory application in the EU for a single-tablet, two-drug regimen of dolutegravir and lamivudine for the first-line treatment of HIV-1 infection.

  • Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
    Market Realist4 days ago

    Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval

    On September 14, Teva Pharmaceutical Industries (TEVA) announced the FDA approval of Ajovy (fremanezumab), its injectable migraine drug. Following the news, a number of analysts raised their recommendations and target prices on Teva Pharmaceutical Industries.

  • How Pharmaceutical ETFs Have Performed in 2018
    Market Realist4 days ago

    How Pharmaceutical ETFs Have Performed in 2018

    Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.

  • Competition Dynamics for Ajovy—Teva’s Migraine Drug
    Market Realist4 days ago

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Teva Pharmaceutical Industries (TEVA) received FDA approval for its Ajovy (fremanezumab-vfrm) injectable on September 14. The chart below shows the company’s quarterly sales trend. The marketing application for Ajovy was filed by Teva in Europe in February. Teva’s (TEVA) Ajovy is an anti-CGRP (calcitonin gene-related peptide) migraine prevention treatment and offers monthly and quarterly dosage options.

  • These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
    Market Realist4 days ago

    These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018

    The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.

  • MarketWatch4 days ago

    Teva stock surges 7% after FDA approves migraine medication

    Teva Pharmaceutical Industries Ltd. shares surged nearly 7% in Monday premarket trade after the company's migraine therapy, intended to prevent chronic attacks of head pain along with other severe, disabling symptoms, was approved by the U.S. Food and Drug Administration. The therapy, Ajovy, is administered as an injection, using a prefilled syringe, and can be dosed on a quarterly or monthly basis. The monthly dose will cost $575 per dose and the quarterly dose will cost $1,725, Teva said, meaning the product's total yearly cost will be about $6,900 per year irrespective of dose. The pricing figures released by Teva refer to the therapy's wholesale acquisition cost, or the price a drugmaker offers wholesalers, from which discounts are typically taken. About 38 million Americans, or 12% of the population, experience migraines, and though the treatment landscape has been sparse so far, it is poised to become increasingly competitive. Another preventative therapy, from Amgen Inc. and Novartis AG [S: nvs] was approved by the FDA in May, and the companies cited the same price tag, or $6,900. A FDA decision for another drug in this class, from Eli Lilly & Co. , is expected in the near future as well. For the beleaguered Teva, the new approval is a "clear positive," said J.P. Morgan analyst Chris Schott, though he noted "the highly competitive dynamics in the space with Amgen, Teva and Lilly all launching within six months of each other and with relatively limited differentiation among agents." Schott expects Teva's migraine therapy could sell about $150 million next year and as much as $600 million by 2022; even so, he sees "few growth drivers or pipeline assets beyond Ajovy" given generic competition for the company's flagship multiple sclerosis medication and challenging conditions for generic drugs. Shares of the U.S.-listed Teva have surged 20.6% year-to-date, while the S&P 500 has risen 8.7% and the Dow Jones Industrial Average has lifted 5.8%.

  • Barrons.com6 days ago

    Eli Lilly Is Selling More Shares of This Biopharma Firm

    INSIDE SCOOP (LLY) (LLY) continues to trim its stake in (ZYME) (ZYME). After selling $508,000 of Zymeworks shares in August, Lilly this week sold another $681,130 of shares of the Vancouver-based biopharmaceutical firm.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks7 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • Roche's Child Arthritis Drug's New Formulation Gets FDA Nod
    Zacks7 days ago

    Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

    Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.

  • AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia
    Zacks7 days ago

    AstraZeneca's Lumoxiti Gets FDA Nod for Hairy Cell Leukemia

    AstraZeneca's (AZN) rare blood cancer candidate receives approval from the FDA for relapsed or refractory hairy cell leukemia (HCL) in patients who have received at least two prior systemic therapies.

  • Elanco CEO on IPO, animal health focus
    CNBC Videos17 hours ago

    Elanco CEO on IPO, animal health focus

    Jeff Simmons, Elanco CEO, discusses the animal health company's initial public offering at the NYSE.